AU2024227044A1 — Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Assigned to Alnylam Pharmaceuticals Inc · Expires 2024-12-19 · 1y expired
What this patent protects
OF THE INVENTION The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO Igene, and methods of using such RNAi agents to inhibit expression of HAO1 and 5 methods of treating subjects having, e.g., PHI.
USPTO Abstract
OF THE INVENTION The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO Igene, and methods of using such RNAi agents to inhibit expression of HAO1 and 5 methods of treating subjects having, e.g., PHI.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.